Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19

In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retros...

Full description

Bibliographic Details
Authors: Bodro, Marta|||0000-0002-0520-8279, Cofan, Frederic|||0000-0003-4163-9620, Ríos, José|||0000-0002-0716-8784, Herrera, Sabina|||0000-0002-5057-354X, Linares González, Laura|||0000-0001-5738-631X, Marcos, María Ángeles|||0000-0002-5019-4873, Soriano Viladomiu, Alex|||0000-0002-9374-0811, Moreno Camacho, Asunción|||0000-0001-6382-0039, Diekmann, Fritz|||0000-0001-6199-3016
Format: article
Publication Date:2021
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:238472
Online Access:https://ddd.uab.cat/record/238472
https://dx.doi.org/urn:doi:10.3390/jcm10081551
Access Level:Open access
Keyword:COVID-19
Kidney transplantation
Anti-cytokine therapy
Mortality
Infection
id ES_1eae64fa6c986fe0bf39de30bf41a2c8
oai_identifier_str oai:ddd.uab.cat:238472
network_acronym_str ES
network_name_str España
repository_id_str
spelling Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19Bodro, Marta|||0000-0002-0520-8279Cofan, Frederic|||0000-0003-4163-9620Ríos, José|||0000-0002-0716-8784Herrera, Sabina|||0000-0002-5057-354XLinares González, Laura|||0000-0001-5738-631XMarcos, María Ángeles|||0000-0002-5019-4873Soriano Viladomiu, Alex|||0000-0002-9374-0811Moreno Camacho, Asunción|||0000-0001-6382-0039Diekmann, Fritz|||0000-0001-6199-3016COVID-19Kidney transplantationAnti-cytokine therapyMortalityInfectionIn the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/238472https://dx.doi.org/urn:doi:10.3390/jcm10081551reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2384722026-06-06T12:50:31Z
dc.title.none.fl_str_mv Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
spellingShingle Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
Bodro, Marta|||0000-0002-0520-8279
COVID-19
Kidney transplantation
Anti-cytokine therapy
Mortality
Infection
title_short Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_full Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_fullStr Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_full_unstemmed Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
title_sort Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
dc.creator.none.fl_str_mv Bodro, Marta|||0000-0002-0520-8279
Cofan, Frederic|||0000-0003-4163-9620
Ríos, José|||0000-0002-0716-8784
Herrera, Sabina|||0000-0002-5057-354X
Linares González, Laura|||0000-0001-5738-631X
Marcos, María Ángeles|||0000-0002-5019-4873
Soriano Viladomiu, Alex|||0000-0002-9374-0811
Moreno Camacho, Asunción|||0000-0001-6382-0039
Diekmann, Fritz|||0000-0001-6199-3016
author Bodro, Marta|||0000-0002-0520-8279
author_facet Bodro, Marta|||0000-0002-0520-8279
Cofan, Frederic|||0000-0003-4163-9620
Ríos, José|||0000-0002-0716-8784
Herrera, Sabina|||0000-0002-5057-354X
Linares González, Laura|||0000-0001-5738-631X
Marcos, María Ángeles|||0000-0002-5019-4873
Soriano Viladomiu, Alex|||0000-0002-9374-0811
Moreno Camacho, Asunción|||0000-0001-6382-0039
Diekmann, Fritz|||0000-0001-6199-3016
author_role author
author2 Cofan, Frederic|||0000-0003-4163-9620
Ríos, José|||0000-0002-0716-8784
Herrera, Sabina|||0000-0002-5057-354X
Linares González, Laura|||0000-0001-5738-631X
Marcos, María Ángeles|||0000-0002-5019-4873
Soriano Viladomiu, Alex|||0000-0002-9374-0811
Moreno Camacho, Asunción|||0000-0001-6382-0039
Diekmann, Fritz|||0000-0001-6199-3016
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
Kidney transplantation
Anti-cytokine therapy
Mortality
Infection
topic COVID-19
Kidney transplantation
Anti-cytokine therapy
Mortality
Infection
description In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/238472
https://dx.doi.org/urn:doi:10.3390/jcm10081551
url https://ddd.uab.cat/record/238472
https://dx.doi.org/urn:doi:10.3390/jcm10081551
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404355261628416
score 15,301629

Similar Items